- Glenn Hearson
A potential new medicine for severe asthma the #SWIFT-1 Study
We will shortly be commencing recruitment into a new asthma trial sponsored by GlaxoSmithKline (GSK) called SWIFT-1
A 52-week, randomised, double-blind, placebo-controlled, parallel group multi-centre study of the efficacy and safety of GSK3511294 adjunctive therapy in adult and adolescent participants with severe uncontrolled asthma with an eosinophilic phenotype (SWIFT-1)
The investigator leading the study at Nottingham is Professor Tim Harrison from the NIHR Nottingham Biomedical Research Centre and the University of Nottingham. The study is being delivered at Nottingham by our Asthma Team led by Liz Dark.
What is this study trying to find out?
GSK3511294 (called the “study drug”) is being tested as a potential new medicine for severe asthma and is not yet approved to treat patients with asthma.
GSK3511294 is a type of medicine called a monoclonal antibody that is made in the laboratory. It works by blocking a specific protein in the body called interleukin-5 which is involved in the severity of asthma and inflammation of the lungs.
This clinical research study is being done to learn whether GSK3511294 works, is safe, and has any side effects when given as an additional therapy.
The study drug works the same way as 3 already approved asthma medications: mepolizumab, reslizumab, and benralizumab. These medications are taken every 4 to 8 weeks. However, it is hoped that the effect of the study drug will last over a longer period of time, so it can be given twice a year (once every 26 weeks).
For more information contact: Tina Wilkinson